BRIEF-TapImmune announces phase 2 ovarian cancer trial study with Astrazeneca By: Reuters: Company News April 21, 2016 at 10:44 AM EDT * TapImmune announces phase 2 ovarian cancer trial study with Astrazeneca/Medimmune and Sloan Kettering Cancer Institute Read More >> Related Stocks: Astrazeneca Plc ADR